

United States Facent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/689,343	10/12/2000		Romualdas Vaisvila	NEB-181	7976	
28986	7590	05/03/2002				
NEW ENGLAND BIOLABS, INC.			EXAMI	EXAMINER		
32 TOZER F BEVERLY,		915		GUZO, I	DAVID	
				ART UNIT	PAPER NUMBER	
				1636	9	
				DATE MAILED: 05/03/2002	٥	

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trade k Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

CONTROL NO. PATENT IN REEXAMINATION		PMARINER	
APPLICATION NO./ FILING DATE FIRST NAMED INVENTOR / ATTORNEY DOCKET N	 FILING DATE	 ATTORNEY DOCKET NO	

EXAMINER

ART UNIT PAPER

8

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

-SEE ATTACHMENT-



Art Unit: 1636

Attachment

The reply filed 4/4/02 is not fully responsive to the Office communication mailed 3/19/02 for the reason(s) set forth below or on the attached Notice To Comply With The Sequence Rules or Raw Sequence Error Report.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE** (1) **MONTH** or **THIRTY** (30) **DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo whose telephone number is (703) 308-1906. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding or relating to attachments to this Office Action should be directed to Patent Analyst Zeta Adams whose telephone number is (703) 305-3291.

David Guzo April 30, 2002

DAVID GUZO BIMARY EXAMINER

MOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements o - 1.825. Applicant's attention is directed to these regulations, published	f 37 CFR	1.821 4 OG 29,
- 1.825. Applicant's attention is directed to these regularization is directed to these regularization. I		
2. This application does not contain, as a separate part of the dis	closure	on
caper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).		
3. A copy of the "Sequence Listing" in computer readable form has n	ot been	
submitted as required by 37 CFR 1.821(e).		•
	•	
4. A copy of the "Sequence Listing" in computer readable form has h	een subr	nitted.
However, the content of the computer readable form does not comply with th of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the mar Sequence Listing."	e requir	ements
5. The computer readable form that has been filed with this application	ition ha	s been .
found to be damaged and/or unreadable as indicated on the attached CRF Dis Report. A substitute computer readable form must be submitted as required 1.825(d).	kette Pr	coptem
6. The paper copy of the "Sequence Listing" is not the same as the	compute	r
readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).		
	•	
7.		
7. Other:		
	(.
Other:	(Sequence	(
Applicant must provide:	(Sequence	(
Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Listing" An initial or substitute paper copy of the "Sequence Listing", as well as the substitute paper copy of the "sequence Listing".		
Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Listing" An initial or substitute paper copy of the "Sequence Listing", as we amendment directing its entry into the specification	vell as	an
Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Listing" An initial or substitute paper copy of the "Sequence Listing", as we amendment directing its entry into the specification	vell as	an
Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Listing" An initial or substitute paper copy of the "Sequence Listing", as well as the substitute paper copy of the "sequence Listing".	vell as	an the same
Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Listing" An initial or substitute paper copy of the "Sequence Listing", as we amendment directing its entry into the specification A statement that the content of the paper and computer readable copy and, where applicable, include no new matter, as required by 37 CF	vell as one pies are	an the same (e) Or

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400